Literature DB >> 7978088

Carbohydrate-deficient transferrin as a measure of immoderate drinking: remaining issues.

J P Allen1, R Z Litten, R F Anton, G M Cross.   

Abstract

A growing body of investigations demonstrate that elevated levels of carbohydrate-deficient transferrin (CDT) effectively distinguishes alcoholics recently consuming large amounts of alcohol from light social drinkers or teetotalers. Nevertheless, important questions still remain concerning the value of CDT as a more generalized marker of alcohol consumption. Most important, the nature of the drinking pattern, including quantity and frequency, necessary to raise levels of CDT significantly remains unclear. Neither has research convincingly demonstrated that CDT is as accurate a marker for women, young adults, or non-Caucasian ethnic groups as for White, middle-aged men. Whereas CDT might serve as a useful outcome measure in trials of alcoholism treatment effectiveness, current research suggests that CDT is of limited value in identifying problematic drinking in general medical or community settings in which a broad continuum of drinkers is represented. Combining CDT with other biochemical or self-report screening measures may, however, improve sensitivity in these contexts. At present, the most accurate laboratory technique to detect CDT seems to be isoelectric focusing. Additional research, however, is needed to resolve the issue of whether CDT is best quantitated as a simple value or if its ratio to total transferrin or non-CDT results in higher predictive validity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7978088     DOI: 10.1111/j.1530-0277.1994.tb00043.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  9 in total

1.  Selection of a substance use disorder diagnostic instrument by the National Drug Abuse Treatment Clinical Trials Network.

Authors:  Robert F Forman; Dace Svikis; Ivan D Montoya; Jack Blaine
Journal:  J Subst Abuse Treat       Date:  2004-07

2.  Changes in serum carbohydrate-deficient transferrin and gammaglutamyl transferase after moderate wine consumption in healthy males.

Authors:  E Randell; E P Diamandis; D M Goldberg
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

3.  Early adolescent symptoms of social phobia prospectively predict alcohol use.

Authors:  Jennifer Dahne; Anne N Banducci; Gretchen Kurdziel; Laura MacPherson
Journal:  J Stud Alcohol Drugs       Date:  2014-11       Impact factor: 2.582

4.  Validity of carbohydrate deficient transferrin and other markers as diagnostic aids in the detection of alcohol related seizures.

Authors:  G Bråthen; K S Bjerve; E Brodtkorb; G Bovim
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

5.  Discrepancy between how children perceive their own alcohol risk and how they perceive alcohol risk for other children longitudinally predicts alcohol use.

Authors:  Andres De Los Reyes; Elizabeth K Reynolds; Frances Wang; Laura MacPherson; C W Lejuez
Journal:  Addict Behav       Date:  2010-07-17       Impact factor: 3.913

6.  Changes in sensation seeking and risk-taking propensity predict increases in alcohol use among early adolescents.

Authors:  Laura MacPherson; Jessica F Magidson; Elizabeth K Reynolds; Christopher W Kahler; C W Lejuez
Journal:  Alcohol Clin Exp Res       Date:  2010-05-17       Impact factor: 3.455

7.  Should we use carbohydrate deficient transferrin as a marker for alcohol abusers?

Authors:  Subir Kumar Das; D M Vasudevan
Journal:  Indian J Clin Biochem       Date:  2004-07

8.  Determination of carbohydrate-deficient transferrin in a Han Chinese population.

Authors:  Binbin Song; Jing Zhu; Jiong Wu; Chunyan Zhang; Beili Wang; Baishen Pan; Wei Guo
Journal:  BMC Biochem       Date:  2014-02-27       Impact factor: 4.059

Review 9.  Focus on: biomarkers of fetal alcohol exposure and fetal alcohol effects.

Authors:  Ludmila N Bakhireva; Daniel D Savage
Journal:  Alcohol Res Health       Date:  2011
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.